SPDR® S&P Biotech ETF

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for United Therapeutics

    In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.

    By Margaret Patrick
  • uploads///goldcboe
    Company & Industry Overviews

    How Stocks and Bonds Reacted to Trump’s Victory

    The CBOE Volatility Index suddenly rose 6.0% on November 9, 2016, after it was clear that Trump had unexpectedly clinched the election.

    By Russ Koesterich, CFA
  • uploads///Chart
    Earnings Report

    A Look at Ionis’s Revenue Streams in the Second Quarter

    Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    A Look at Incyte’s Valuation as of May 25

    Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Why Eylea Could Face Tough Competition in 2016

    In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.

    By Margaret Patrick
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally

    Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    How Did Ziopharm Keep XBI from Losing More Ground?

    Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV ratio of 10.1x.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Alexion Continues to Rise on FDA’s Approval of Kanuma

    Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.

    By Peter Neil
  • uploads///hemophilia drugs
    Company & Industry Overviews

    What Are the Current Treatment Options for Hemophilia?

    Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.

    By Jillian Dabney
  • uploads///tablets _
    Earnings Report

    Biogen Stock Trending Higher on Strong Q2 2018 Results

    Today, Biogen (BIIB) announced its earnings results for the second quarter of fiscal 2018. Here’s what you need to know.

    By Sarah Collins
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Baxalta in the XBI Top Ten Large Caps

    Baxalta (BXLT) rose by 6.2% for the week ending October 16, 2015. The stock rose as it received the Health Canada Approval for OBIZUR.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics Expected to Report Flat Revenue Growth in Fiscal 2018

    Myriad Genetics (MYGN) expects to report revenues in the range of $750 million–$770 million in fiscal 2018 (ended June 30, 2018).

    By Margaret Patrick
  • uploads///Graph Part
    Company & Industry Overviews

    Incyte Was a Star Performer from August 10–17, 2015

    By market cap size, Incyte (INCY) is among the top ten holdings of the SPDR S&P Biotech ETF (XBI). Incyte has a weight of 1.22% in XBI’s portfolio.

    By Peter Neil
  • uploads///Sharpe Ratio Formula
    Healthcare

    Why you should use the Sharpe ratio when investing in the medical device industry

    What is a Sharpe ratio? A Sharpe ratio is a tool that measures the amount of returns for each unit of volatility that’s generated by a portfolio (higher returns and lower volatility equals more returns per unit of volatility). The measurement allows investors to analyze how much return they’re receiving from a portfolio in exchange for […]

    By Amritpal Khalsa
  • uploads///sw
    Company & Industry Overviews

    Why Portola Pharmaceuticals Rose 8.09% on January 4

    On January 4, Portola Pharmaceuticals stock closed at $19.38, an ~8.09% increase from its prior close of $17.93 on January 3,

    By Daniel Collins
  • uploads///medic _
    Company & Industry Overviews

    Why Clovis Oncology Stock Rose 48% in November

    On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.

    By Daniel Collins
  • uploads///lab _
    Company & Industry Overviews

    Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday

    On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results

    On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Cara Therapeutics: Performance and Estimates for Q3

    Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Revenue Growth Rate

    Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Here Are the Key Products in Sage’s GABA Receptor Portfolio

    Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///hospital _
    Company & Industry Overviews

    Bluebird Bio’s Valuation on September 6

    Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.

    By Mike Benson
  • uploads///microscope _
    Earnings Report

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What to Expect from Sarepta’s Second-Quarter Earnings

    Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Sage Therapeutics’ GABA Receptor–Based Products

    On June 12, Sage Therapeutics announced its expedited development plan for SAGE-217.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    How Ionis Pharmaceuticals’ Valuation Compares

    Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Intellia Therapeutics Stock Fell 9.8% on Monday

    On June 11, Intellia stock fell 9.8% to close at $24.56 over concerns of the CRISPR-CAS9 Gene Therapy.

    By Mike Benson
  • uploads///PART  Direxion
    Healthcare

    Biotech Sector Continue to Dazzle Despite Market Distress

    Biotech stocks—with their binary outcomes and potential FDA approvals or denials—should whip around, pending various outcomes.

    By Direxion
  • uploads///dna _
    Company & Industry Overviews

    Viking Therapeutics Stock Rose 101% on May 31

    On May 31, Viking Therapeutics (VKTX) closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97.

    By Sarah Collins
  • uploads///pain injection market
    Company & Industry Overviews

    Why the Physician Office Pain Management Market Matters to MiMedx

    Through MiMedx’s donor program, a mother scheduled to deliver a baby by C-section can donate her placental tissue rather than leave it as medical waste.

    By Kenneth Smith
  • uploads///Cara SGA
    Company & Industry Overviews

    Comparing Cara Therapeutics’ Financial Performance

    Financial performance In 3Q17, Cara Therapeutics (CARA) incurred $9.6 million in research and development expenses, compared with $9.1 million in 3Q16. This fall in expenses was due to a $3.1 million decrease in expenses for oral CR845’s Phase 2B clinical trial, and partially offset by increased expenses for its intravenous CR845 safety study. Meanwhile, the company’s general and administrative expenses rose from […]

    By Kenneth Smith
  • uploads///RDUS pipeline
    Company & Industry Overviews

    A Strong Pipeline of Drugs Bodes Well for Radius Health

    The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Patisiran Expected to Become Key Growth Driver for Alnylam

    Alnylam Pharmaceuticals’ (ALNY) investigational drug Patisiran is expected to target 20,000 to 30,000 patients with hereditary ATTR (or hATTR) Amyloidosis with polyneuropathy caused by amyloid deposition in nerves.

    By Margaret Patrick
  • uploads///A Fund details
    Healthcare

    Benefitting from IBB’s Lower Expense Ratio

    The iShares NASDAQ Biotechnology ETF (IBB) is an open-end fund with assets under management of $9.85 billion.

    By Peter Barnes
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Acadia Pharmaceuticals in September

    Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”

    By Margaret Patrick
  • uploads///part  table
    Real Insights

    Are Stock Returns during Summer Months That Bad?

    The health care sector (IBB) (VHT) (XBI) has been the most challenged sector since Donald Trump’s presidential campaign.

    By Direxion
  • uploads///Healthcare Sector Outperforming Overall Market Since
    Macroeconomic Analysis

    The Larger Aims of Obamacare: An Overview

    The idea behind Obamacare was that it would embody legislation not only providing but mandating healthcare coverage for nearly everyone in the US.

    By Mary Sadler
  • uploads///Rising consumer sentiment helping the market rally in
    Company & Industry Overviews

    Is Rising Consumer Sentiment Helping the Market Rally in 2017?

    The S&P 500 Index (SPX-INDEX) has posted a rise of ~5% since the beginning of 2017, with banks and energy stocks leading the rally as of March 29, 2017.

    By Mary Sadler
  • uploads///ANR
    Company & Industry Overviews

    What Do Analysts Recommend for Gilead Sciences Stock?

    According to a Reuters consensus of 26 brokerage firms on November 22, 2016, 88% of the analysts recommended Gilead as a “buy.”

    By Jillian Dabney
  • uploads///demorepub
    Company & Industry Overviews

    Which S&P 500 Sectors Do the Best for an Incumbent Democrat?

    The S&P 500 returns for a second-term president have been somewhat better than a first-term president, which is one reason for the incumbency factor.

    By Amanda Lawrence
  • uploads///Graph
    Company & Industry Overviews

    $1 Billion Sales Target in Place for Tyvaso

    United Therapeutics’ Tyvaso’s strong profile and patent protection until the late 2020s is expected to enable it to reach annual sales of $1 billion.

    By Margaret Patrick
  • uploads///soliris opportunity
    Earnings Report

    How Significant Is Alexion’s Opportunity with Soliris?

    Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.

    By Jillian Dabney
  • uploads///spdr
    Macroeconomic Analysis

    FOMC Keeps the Door Open for a Live Meeting in September

    The Fed had a meeting on July 27 to decide on the monetary policy. The tone of the Fed’s statement made a case for the September meeting to be a live one.

    By David Meyer
  • uploads///Chart
    Company & Industry Overviews

    The Novartis-Xencor Collaboration Agreement: The Details

    Novartis, one of the largest pharmaceutical companies, announced a collaboration and licensing agreement with Xencor on June 28, 2016.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Understanding the Sales Potential of United Therapeutics’ Orenitram

    United Therapeutics’ (UTHR) Orenitram is an oral medication containing the prostacyclin analogue, trepostinil.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    How Are XBI’s Holdings’ Moving Averages Trending?

    On June 8, 2016, 77% of XBI’s stocks were trading above their 20-day moving averages, 69% were trading above their 50-day moving averages, and 69% were trading above their 100-day moving averages.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Agios Stock Rises on Higher Trading Volumes on June 8

    Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    BioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5%

    As of June 1, 2016, BioMarin Pharmaceutical (BMRN) was the most underperforming stock among the large-cap stocks of the SPDR S&P Biotech ETF (XBI).

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI Tops the Biotechnology ETFs in the Last Week of May

    In the week ending May 27, 2016, the SPDR S&P Biotech ETF (XBI) was the top performer among biotechnology ETFs with a return of 5.1%.

    By Peter Neil
  • uploads///Xtandi opporunity
    Company & Industry Overviews

    Opportunities For Xtandi, Medivation’s Key Drug

    Enzalutamide, known by its brand name Xtandi, is an androgen receptor inhibitor. It is the only commercialized product in Medivation’s (MDVN) portfolio.

    By Jillian Dabney
  • uploads///SPDR Apr
    Macroeconomic Analysis

    SPDR Indexes across Energy and Gold Rise on Increase in Commodities

    The SPDR S&P Metals & Mining ETF (XME) was the outperformer of the day on April 19.

    By David Meyer
  • uploads///Chart
    Company & Industry Overviews

    Analyst Estimates for Ionis Pharmaceuticals’ 2016 Revenue

    Analyst estimates show Ionis Pharmaceuticals’ 2016 revenue at $237 million. That’s a decline of more than 16% compared to $284 million for 2015.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Incyte Continues Its Growth Spree in 2015

    Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Will Elagolix Make Neurocrine Biosciences a Key Women’s Health Name?

    If approved, Elagolix could present fierce competition for existing drugs like Teva Pharmaceuticals’ (TEVA) Aygestin and Astrazeneca’s (AZN) Zoladex.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI Mid-Cap News: Look Who Took a Beating on March 23

    Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI News as of March 16: Mid-Caps Under Pressure

    Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI on a Downward Slope, but How Steep?

    On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    DaVita’s Stock Reacts to the Merger with The Everett Clinic

    DaVita HealthCare Partners (DVA) was one of the biggest winners for the week ending March 4 with a return of 6.1%.

    By Peter Neil
  • uploads///SPDR Mar
    Macroeconomic Analysis

    Energy and Mining SPDRs Rally as Services Sector Declines

    The metals and mining and oil production sectors took positive cues as commodity prices continued the rally on March 3, 2016. XOP was the outperformer among major sector-specific ETFs.

    By David Meyer
  • uploads///Revlimid Revenue Part
    Earnings Report

    Revlimid Continues to Drive Celgene’s Revenue

    Revlimid (lenalidomide) is one of Celgene’s (CELG) main revenue drivers. It had revenues of $1.4 billion in 3Q15, excluding the adverse impact of foreign exchange fluctuations.

    By Peter Neil
  • uploads///Graph vimizim
    Company & Industry Overviews

    Vimizim: A Recent Addition to BioMarin’s Portfolio

    In 2014, Vimizim (elosulfase alfa) received marketing approval by the FDA, followed by the approval of the European Medicines Agency for treating MPS IV A.

    By Jillian Dabney
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Vertex Pharmaceuticals Brings up the Rear among XBI’s Large-Caps on December 3

    Vertex Pharmaceuticals lost the most among the large-cap stocks on December 3, closing at $122.06—a decline of 6.4%.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    The SPDR S&P Biotech ETF Lingers in the Red as of December 3

    The SPDR S&P Biotech ETF (XBI) went down by 3.9% on December 3, which represents the third consecutive day of declines for the ETF. XBI closed at $68.91.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    AbbVie Topped XBI’s Large-Cap Space

    AbbVie (ABBV) rose 6.5% on November 2, 2015. The stock has continued its strong run and has now gained for seven consecutive trading sessions.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    BioMarin Falls 16.81% in Week Ended September 25

    BioMarin Pharmaceutical (BMRN) fell 16.81% and closed at $108.69 last week. That’s below the 20-day, 50-day, and 100-day moving averages. The 14-day RSI was 28, or oversold territory.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    IBB Mid-Cap Outperforms XBI Mid-Cap

    IBB mid-cap outperformed XBI mid-cap for the week ended September 4, 2015. The IBB top ten mid-cap stocks returned -3.34%, while the XBI top ten mid-cap stocks returned -4.33% for the same period.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Top Ten of XBI Outperform by Market Cap

    The average return of the top ten IBB stocks was -4.73%, while the average return of top ten XBI stocks was -3.89% for the week ended September 4, 2015.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Alnylam and ISIS Lead Mid-Cap Stocks

    Alnylam and ISIS led mid-cap stocks from August 25–31, 2015. Alnylam Pharmaceuticals (ALNY) has a weight of 1.60% in IBB and 1.15% in XBI. The stock gained 10.89% in that period.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Top Ten XBI Stocks by Market Cap Outperform August 25–31

    The top ten stocks of the SPDR S&P Biotech ETF (XBI) outperformed the top ten stocks of the iShares Nasdaq Biotechnology ETF (IBB) and the Health Care Select Sector SPDR ETF (XLV) for August 25–31.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Comparing IBB’s and XBI’s Small-Cap Stocks

    From August 10–17, 2015, the XBI top ten small-cap stocks outperformed the IBB’s top ten small-cap stocks. XBI small caps returned 1.04% while IBB small caps rose by 0.07% during the same period.

    By Peter Neil
  • uploads///MA Chart
    Company & Industry Overviews

    How Actavis Has Emerged through Mergers and Acquisitions

    In October 2012, Actavis completed the acquisition of Actavis Group. In 2013, the company’s revenues outside the US increased to 29% from 16% in 2012.

    By Nicole Sario
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.